The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

XTalks

APRIL 7, 2021

COVID-19 antibody tests can help identify people who may have had prior COVID-19 infection, and importantly, asymptomatic individuals with a developing or current infection. The tests do not detect the SARS-CoV-2 virus itself, and hence should not be used for diagnostic purposes.

Antibody 102

Antibody Immune Response Radiology Marketing 102

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. The products encompass molecular, antigen and T cell-based testing approaches.

Protein 98

Protein RNA Antibody Production 98

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800. It will be funded by the U.S.

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. W911QY-21-9-0001.

Antibody 52

Antibody In-Vivo In-Vitro Vaccination 52

The Pharma Data

MARCH 25, 2022

” Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “Today’s positive CHMP recommendation represents a significant step forward in our ongoing efforts to introduce additional, important preventative measures for people in Europe at higher risk of developing COVID-19. W911QY-21-9-0001.

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

Bioengineer

JULY 15, 2021

.” Immunotherapy has revolutionized cancer treatment by helping patients’ immune systems fight off cancer. Boosted by the immunotherapy, the immune cells attacked the cancer cells that had been damaged by the radiotherapy. This agent was developed by one of the co-authors, Jamey Weichert, Ph.D., ” ###.

Medicine 52

Medicine Clinical Trials Clinical Trials Scientist 52